Skip to main content

Advertisement

Log in

Mechanisms of Action of Intravenous Immunoglobulin in Inflammatory Muscle Disease

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Intravenous immunoglobulin (IVIG) is a unique immune-modulating therapy that has a wide range of effects on the immune system at multiple levels. This allows it to be used successfully in a variety of immune-mediated, systemic, and neurological disorders, including the inflammatory myopathies. It is likely that the specific action of IVIG varies depending on the underlying pathogenesis of a given disease. In dermatomyositis (DM), IVIG has been shown to diminish the activity of complement and deposition of membrane attack complex on capillaries and muscle fibers, the expression of adhesion molecules, and cytokine production. IVIG also appears to modify gene expression in the muscle of DM patients. The mechanism by which IVIG affects muscle in polymyositis and inclusion body myositis has not been well-studied. However, it may work via suppression of T-cell activation (including cytotoxic T cells) and migration into muscle tissue and alterations in cytokine production. IVIG generally yields the greatest therapeutic benefit in DM and is often of marginal utility in inclusion body myositis. It is generally considered as second-line or adjunctive therapy in the inflammatory myopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–31.

    Article  PubMed  CAS  Google Scholar 

  2. Bussel JB, Kimberly RP, Inman RD, et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood. 1983;62:480–6.

    PubMed  CAS  Google Scholar 

  3. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol. 1983;22:205–12.

    Article  PubMed  CAS  Google Scholar 

  4. Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;1:406–7.

    Article  PubMed  CAS  Google Scholar 

  5. •• Donofrio PD, Berger A, Brannagan 3rd TH, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM Ad Hoc Committee. Muscle Nerve. 2009;40:890–900. This report from the American Academy of Neuromuscular and Electrodiagnostic Medicine Task Force provides a comprehensive, evidence-based consensus statement on the treatment of immune-mediated neuromuscular disorders with IVIG.

    Article  PubMed  CAS  Google Scholar 

  6. Schroeder Jr HW, Cavacini L. Structure and function of Immunoglobulins. J Allergy Clin Immunol. 2010;125:S41–52.

    Article  PubMed  Google Scholar 

  7. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747–55.

    Article  PubMed  CAS  Google Scholar 

  8. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 1988;25:41–8.

    Article  PubMed  CAS  Google Scholar 

  9. Tha-In T, Metselaar HJ, Tilanus HW, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood. 2007;110:3253–62.

    Article  PubMed  CAS  Google Scholar 

  10. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758–65.

    Article  PubMed  CAS  Google Scholar 

  11. Liblau R, Gajdos P, Bustarret FA, et al. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol. 1991;11:128–31.

    Article  PubMed  CAS  Google Scholar 

  12. Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol. 1993;92(3):369–72.

    Article  PubMed  CAS  Google Scholar 

  13. Diegel ML, Rankin BM, Bolen JB, et al. Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem. 1994;269:11409–16.

    PubMed  CAS  Google Scholar 

  14. Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161:3781–90.

    PubMed  Google Scholar 

  15. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729–35.

    Article  PubMed  CAS  Google Scholar 

  16. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol. 2006;6:528–34.

    Article  PubMed  CAS  Google Scholar 

  17. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.

    Article  PubMed  CAS  Google Scholar 

  18. Hurnaus S, Mueller-Felber W, Pongratz D, et al. Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders. Eur Neurol. 2006;55:204–8.

    Article  PubMed  CAS  Google Scholar 

  19. Carmeli E, Moas M, Reznick AZ, Coleman R. Matrix metalloproteinases and skeletalmuscle: a brief review. Muscle Nerve. 2004;29:191–7.

    Article  PubMed  CAS  Google Scholar 

  20. Ott VL, Fong DC, Cambier JC, et al. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001;108:S95–8.

    Article  PubMed  CAS  Google Scholar 

  21. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484–6.

    Article  PubMed  CAS  Google Scholar 

  22. • Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins—understanding properties and mechanisms. Clin Exp Immunol. 2009;58 Suppl 1:2–13. This review provides an excellent overview of some of the known mechanisms of action for IVIG and details how varied mechanisms may be relevant in different diseases.

    Article  Google Scholar 

  23. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.

    Article  PubMed  CAS  Google Scholar 

  24. Amemiya K, Semino-Mora C, Granger RP, et al. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 2000;94:99–104.

    Article  PubMed  CAS  Google Scholar 

  25. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005;128:1887–96.

    Article  PubMed  Google Scholar 

  26. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008–19.

    Article  PubMed  Google Scholar 

  27. Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology. 2000;54:65–71.

    PubMed  CAS  Google Scholar 

  28. • Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:346–52. This reference describes some of the recent controversies in the proposed pathophysiology of the inflammatory myopathies and critically appraises the evidence behind the different theories.

    Article  PubMed  CAS  Google Scholar 

  29. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467–74.

    Article  PubMed  CAS  Google Scholar 

  30. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991;91:162–8.

    Article  PubMed  CAS  Google Scholar 

  31. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6.

    PubMed  CAS  Google Scholar 

  32. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43:876–9.

    PubMed  CAS  Google Scholar 

  33. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology. 1994;44:1516–8.

    PubMed  CAS  Google Scholar 

  34. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323–7.

    PubMed  CAS  Google Scholar 

  35. Dalakas MC. Intravenous immune globulin for dermatomyositis. N Eng J Med. 1994;330:1392–3.

    Google Scholar 

  36. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002;61:37–41.

    Article  PubMed  CAS  Google Scholar 

  37. Kuwano Y, Ihn H, Yazawa N, et al. Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin. Acta Derm Venereol. 2006;86:158–9.

    PubMed  Google Scholar 

  38. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1998;63:107–10.

    Article  Google Scholar 

  39. Williams L, Chang PY, Park E, et al. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. Obstet Gynecol. 2007;109(2 Pt 2):561–3.

    Article  PubMed  CAS  Google Scholar 

  40. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994;21:1092–7.

    PubMed  CAS  Google Scholar 

  41. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis—four year review of nine cases. Arch Dis Child. 1995;72:25–8.

    Article  PubMed  CAS  Google Scholar 

  42. Tsai MJ, Lai CC, Lin SC, et al. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Erke Yi Xue Hui Za Zhi. 1997;38:111–5.

    CAS  Google Scholar 

  43. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis—efficacy and safety. J Rheumatol. 2000;27:2498–503.

    PubMed  CAS  Google Scholar 

  44. Cherin P, Chosidow O, Herson S. Polymyositis and dermatomyositis. Ann Dermatol Venereol. 1995;122:47–54.

    Google Scholar 

  45. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367–75.

    Article  PubMed  CAS  Google Scholar 

  46. Geneway S, Saudan-Kister A, Guerne P-A. Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance treatment is effective. Ann Rheum Dis. 2001;60:635–6.

    Article  Google Scholar 

  47. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22–8.

    Article  PubMed  CAS  Google Scholar 

  48. •• EFNS Task Force on the Use of Intravenous Immunoglobulin in Treatment of Neurological Diseases. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893–908. This paper offers evidence-based recommendations from the European Federation of Neurological Societies Task Force for the use of IVIG in treatment of neurological diseases.

    Article  Google Scholar 

  49. Pongratz D. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis). J Neurol. 2006;253 Suppl 5:V64–5.

    Article  PubMed  Google Scholar 

  50. Recher M, Sahrbacher U, Bremer J, et al. Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatol Int. 2010, Jan 1 (Epub ahead of print).

Download references

Disclosure

Dr. Tandan has served as a consultant for Crescent Healthcare and RxSolutions. Dr. Quick reported no potential conflict of interest relevant to this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rup Tandan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quick, A., Tandan, R. Mechanisms of Action of Intravenous Immunoglobulin in Inflammatory Muscle Disease. Curr Rheumatol Rep 13, 192–198 (2011). https://doi.org/10.1007/s11926-011-0171-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0171-0

Keywords

Navigation